HOME › DRUGS › PNEUMOCOCCAL POLYSACCHARIDE CONJUGATE VACCINE (21-VALENT)
ACTIVE SUBSTANCE / INN

PNEUMOCOCCAL POLYSACCHARIDE CONJUGATE VACCINE (21-VALENT)

Brand name(s): Capvaxive
EMA LISTED
AUTHORISED
Pneumococcal Infections
ACTIVE SUBSTANCE
Pneumococcal Polysaccharide Conjugate Vaccine (21-Valent)
REGULATORS
EMA
SPONSORS / MAH
Merck Sharp & Dohme B.V. 
TOTAL APPLICATIONS
1
EMA AUTHORISATIONS
PRODUCT NAMEHOLDERSTATUSDATEINDICATION
CapvaxiveMerck Sharp & Dohme B.V. Authorised24/03/2025Pneumococcal Infections

FULL INTELLIGENCE ON PNEUMOCOCCAL POLYSACCHARIDE CONJUGATE VACCINE (21-VALENT)

Patent cliffs, clinical trials, pipeline data, AI-enriched regulatory signals — free on PharmaSignal.

OPEN PLATFORM →